MAPT and Alzheimer disease: The full-length hyperphosphorylated tau (referred to as p-tau hence forth) produced by PIMAX bears phosphorylation marks that recapitulate many of those found associated with AD including phosphoepitopes used for AD staging on human postmortem samples, such as p-T181, p-S202, and p-T217 [30, 63, 64], therefore linking this recombinant tau to the disease.